Issue 12 / July 2010

Trognews

Continued Cancer Australia support for TROG!

Inside this issue:

Cancer Australia Funding	1 - 2
Quality Assurance Update	3
ANDROTAT Update	4
2010 TROG Meetings	5 - 7
What's New @ TROG	7
Trial in Profile	8
Trial Updates	9 - 13
TROG Committee	14
TROG COO Contacts	15 - 16
Upcoming Events	17

TROG has been successful in securing further funding through the Cancer Australia *Support for Cancer Clinical Trials* initiative. Ongoing support from Cancer Australia will fund key infrastructure positions and represents an important and efficient investment in research quality, output and sustainability. TROG continues to achieve outstanding growth and success in its research endeavours and as an organisation, made possible by strategic investment in research infrastructure.

TROG received high commendation from the international panel who reviewed the applications. The panel commented on the value for money and track record that TROG has achieved, and recognised the excellent radiotherapy quality assurance services that TROG provides. The provision of radiotherapy quality assurance services is an essential and integral component of TROG's infrastructure. TROG works closely with researchers and maintains ongoing collaborative relationships with other international specialists in radiotherapy research quality assurance, to ensure Australian and New Zealand clinical trials advance in context with worldwide developments.

TROG as Australia and New Zealand's specialist clinical research group for cancers that can be treated with radiotherapy remains dedicated to the control of a wide range of cancers through quality multi-centre research. The core business of TROG, conducting high quality clinical trials in Radiation Oncology, continues to expand, and TROG is now firmly established as a key player in the international trials arena in this discipline.

Continued Cancer Australia support for TROG

Past support from Cancer Australia has enabled TROG to build capacity and add value across the research portfolio, as well as invest our expertise in collaboration with other groups. Growth in patient accrual to TROG trials, growth in TROG membership, and growth in national competitive grant funding are all evidence of this success. TROG trials provide a positive contribution to the body of literature and improvement in standard of care. All of this leads to improved care and outcomes for cancer patients. TROG's strategic plan is focused on growth and sustainability of its research portfolio, coupled with continuous quality improvement. The provision of appropriate infrastructure is essential to underpin these objectives.

By way of track record, TROG was able to highlight the outcomes, achievements and impact of activities funded by the previous Cancer Australia initiative *Support for Cancer Clinical Trials* program (during the period 1 January 2008 to 30 June 2010).

These achievements included:-

Expansion of National and International collaborations - Of the thirteen trials approved by TROG for activation since January 2008, and seven trials currently in development, nine are in collaboration with other trials groups (note: 15 of these trials are randomised). TROG is also actively involved in the COSA & Cooperative Oncology Groups (COGs) enabling grant project. The Executive Officers Network with representatives from all the COGs has adapted and implemented a standard Clinical Trial Agreement for COGs for use in Australia.

Consumer involvement in the protocol development process for TROG trials - The TROG consumer representative has attended all TROG Scientific Committee meetings and Trials Review Meetings which were held during the past period of Cancer Australia funding. The consumer member has also participated in Board and Scientific Committee meetings as well as being involved in the protocol development process by reviewing new trial proposal protocols.

Increased membership of TROG to include members from multiple disciplines - TROG membership has shown a steady increase during the past period of Cancer Australia funding. At Jan 2008 TROG membership was 506 increasing to 708 by 31 Dec 2009. TROG membership is inclusive of full members, life members and affiliate members. Affiliate membership continues to attract a range of medical disciplines including Trial Coordinators, Data Managers, Radiation Therapists, Medical Physicists, Statisticians, Registrars, Medical Oncologists, Surgeons, Nurses and Radiologists.

Presentation of results of TROG trials at national and International meetings - Representatives of TROG have delivered fifty separate presentations since January 2008 at both national and international meetings, effectively communicating the results of TROG trials.

Increased patient participation – TROG's patient accrual had reached 8,573 (as of 31st December 2009) and the remaining goal of 10,000 patients by 2010 is moving closer to realisation with the rapid recruitment of patients to recently activated TROG trials and increasing accrual rates for previously established trials. Since Jan 2008, 17 new trial sites have been approved to recruit patients to TROG trials.

Improved scientific process and outcomes - TROGs strategic goal of 100 publications has been reached, 12 months earlier than anticipated and sixteen competitive grants have been won since the commencement of the funding period, this figure has far exceeded TROGs strategic goal of 10 new competitive grants by 2010.

Central Quality Assurance Service Update

The TROG Central QA Office provides a comprehensive QA facility encompassing a range of essential activities from protocol design to provision of QA reports. New QA resources are developed in context with international clinical trial practice and to respond to the advancement of new technologies and techniques in radiotherapy.

Central Quality Management System (CQMS)

A movie featuring the use of CQMS for RT QA reviews in the TOPGEAR trial is now available via the TROG website (click on 'TROG movies' in the members section).

A current CQMS development project is the integration of Facility Questionnaires (FQ) for QA credentialing. When the FQ data is centrally stored in the secure database, programmed features will enable 'auto-completion' of FQs for future TROG trials. Sites will be able to update their FQ data on-line while reducing the repetition of form completion. QA reviewers will have restricted access to the FQ data to perform specific roles e.g. site credentialing. De-identified summative information, such as generic lists of equipment used in Australia, may be provided to TROG members in future to assist with feasibility discussions for new TROG research proposals or to appropriate organisations associated with TROG credentialing programs e.g. ARPANSA.

SWAN 3D RT Plan Review Software

The central TROG version of the SWAN software is available to QA reviewers via a link in CQMS audit forms. TROG's independent commissioning of version 2.3 is now complete and this version will be available to reviewers shortly. The main change is a memory expansion to facilitate review of plans with large file sizes, eg. multi-phase plans. Very large files may still not open in SWAN. Long CT scan sets (eg. CT image slices >5 from field edges) and/or dose calculation volumes well beyond the irradiated volume can contribute to very large file sizes. If so, please consider if these can be edited without affecting the accuracy of the plan data required for QA review.

Updated treatment planning systems export guidelines are available on the TROG website (click 'QA Program') for Eclipse, Pinnacle, XiO and Oncentra. Following these detailed steps generally ensures the plan data is exported in a format that can be successfully loaded in SWAN. Instructions on exporting two-phase plans are being updated following feedback from users. For assistance please contact the QA office.

QA Helpdesk

A dedicated Helpdesk is available to assist members with any issues they encounter whilst using the QA facilities, including CQMS and SWAN. Please email QA@trog.com.au for queries or to log a helpdesk issue. An update to the helpdesk system is currently in progress to improve feedback to members and facilitate the systematic analysis of issues.

Feedback from TROG members is essential for the ongoing development of central QA facilities. Recent upgrades to CQMS were in response to comments from users regarding improvements to screen displays.

Members can access an e-learning package for both CQMS and SWAN online at www.trog.com.au. Review and update of these training tools will commence shortly – so please forward any feedback on the current e-learning lessons to the TCOO QA office.

TCOO QA Staff

Joan Hatton is currently on leave until mid-September. We welcomed Kelly Barker back from maternity leave in July and she is in the TROG office on Mondays and Tuesdays. Alisha Moore is on maternity leave following the arrival of her daughter Chloe in May – and we extend our warmest congratulations to Alisha and Andrew.

'Assessment of New Radiation Oncology Treatments and Technology' (ANROTAT)

The 'Assessment of New Radiation Oncology Treatments and Technology' (ANROTAT) project involves TROG members and affiliates from throughout Australia and New Zealand and seeks to develop a generic research framework that is capable of collecting and generating information to substantiate the safety, clinical effectiveness and cost effectiveness of new technologies and treatments in Radiation Oncology in Australia. As part of the project, the framework will be piloted to assess Intensity Modulated Radiation Therapy (IMRT) and Image Guided Radiation Therapy (IGRT) in four tumour site-specific projects: Nasopharynx (IMRT), Anal Canal (IMRT), Post-Prostatectomy (IMRT) and Prostate (IGRT).

The focus of work over the past few months has been building this framework. The first step was to undertake a literature review to identify, evaluate and critique previously published frameworks that have been used to assess and appraise new technologies. Additionally, consensus/clinical practice guidelines describing the clinical and technical methodologies required for adherence to research protocols, are being developed based on the best available evidence through consultation with national and international expertise and current scientific literature.

A horizon scan of new technologies and treatments in Radiation Oncology to inform the design, and testing, of the framework has been completed and the final report was provided to the Department of Health and Ageing earlier in the year. It was accompanied by an additional report analysing the potential impact of these technologies and treatments on the Australian health care system.

A Radiation Oncology Registry is also being developed. This will collect and collate quality patient data, to allow analysis of clinical outcomes over time with an operative and methodological process. There has already been extensive consultation with a number of experienced faculties and their associated registries. Existing related data sets have been identified and reviewed with the intent of effectively supplementing these items with a Radiation Oncology specific dataset.

Broad engagement has continued to be supported with a targeted communication strategy and the level of interest in the project from the radiotherapy professions, and the wider cancer sector, remains high.

The ANROTAT project is supported by five TROG Central Operations Office staff; Mel Grand (Project Manager), Michelle Hall (Senior Project Officer), Haylea Cleaver (Junior Project Officer), Celia Burrell and Lou MacGregor (Administrative Officers).

Annual Scientific Meeting

The 2010 TROG Annual Scientific Meeting was held in Queenstown, New Zealand. The meeting attracted a large number of delegates, (over 200 attended), making it the largest ever number of delegates to attend a TROG meeting held in New Zealand. This year again reflects the ongoing growth and increasing profile of our organisation. Special thanks to the major sponsors, Varian, AstraZeneca, and Hospira.

The meeting commenced with the Clinical Trial Management (CTMW) and Technical Research (TRW) Workshops. The CTMW opened with a panel discussion followed by clinical trial management education topics. The panel format provided an opportunity for open discussion and resolution on trial coordination issues. The Good Clinical Practice workshop was held in the afternoon. The workshop was facilitated by Caroline Alsweiler from Green Lane Coordinating Centre.

The TRW sponsored by Varian, provided an excellent opportunity to discuss Radiation Therapy and Medical Physics aspects of trials. The workshop provided opportunity for the group to have split sessions to explore specific issues.

The TROG 2009 Annual Research Report was launched at the Welcome Reception dinner on Wednesday night.

Delegates actively participated in the scientific program and responded to the ASM presentations with questions and constructive feedback for all trials, in particular the new proposals. Our invited guest speakers contributed additional expertise and valuable input to the program with presentations from Dr Paul Keall, (USA), Ms Stephanie Pollard (NZ) and Prof Madeleine King (Aust).

Thursday's social event commenced with a scenic ride on the gondola to access the skyline complex, followed by lugeing, which gave delegates an opportunity to "let their hair down". Just before sunset delegates were able to enjoy the beautiful views of Coronet Peak, The Remarkables mountain range and Lake Wakatipu to Cecil and Walter Peak. A delicious buffet dinner followed.

TROG Conference dinner was held on Friday evening commencing with a spectacular cruise aboard the iconic vintage steamship TSS Earnslaw across Lake Wakatipu to the homestead. Upon reaching Walter Peak homestead a buffet dinner was served. After dinner delegates were led to the shearing shed to view a humorous display of sheep shearing by the resident farmer. During the return journey on TSS Earnslaw the on-board piano accompanied the traditional TROG sing a long.

TROG Awards

The TROG Trial of Excellence Award was presented to Dr Maria Pearse and Dr Andrew Kneebone for TROG Trial 08.03 RAVES: A Phase III multi-centre randomised trial comparing adjuvant radiotherapy (RT) with early salvage RT in patients with positive margins or extraprostatic disease following radical prostatectomy. RAVES – Radiotherapy Adjuvant Versus Early Salvage.

Associate Professor David Ball received the award for Outstanding Contribution to TROG in recognition of his committee representation, trial development and specialist expertise provided to the TROG Program.

The TROG Membership supported the proposal of Life Membership for Dr Peter O'Brien and Professor Lester Peters at the recent Annual General Meeting. Congratulations to all!

SAVE THE DATE: the 2011 Annual Scientific Meeting will be held at the Stamford Grand, Adelaide from 11 April to 14 April 2011, save the date in your diary.

Memories of
TROG Annual Meeting
March 2010
some pictures by Claire Philips

2010 Trials Review Meeting

Incorporating

Health Economics Workshop

This year's Trials Review Meeting (TRM) will be held at Bell City Event Centre from 21 October to 22 October 2010.

The TRM will incorporate a Health Economics Workshop, (to be held on the morning of Thursday 21 October) in recognition of the emerging significance of gathering economic evidence to support future decision making as a core component in the development and conduct of cancer clinical trials. The workshop will be conducted by Professor Deborah Schofield, Merel Kimman and Hannah Verry from NHMRC Clinical Trials Centre.

Registration is now open on the TROG website.

If you would like more information about the TROG Meeting please contact Alyson Segrott Conference Coordinator by E-mail:Alyson.Segrott@trog.com.au or phone +61 2 4014 3911

What's new@

www.trog.com.au

TROG Annual Meeting 2010

The 2010 Annual Meeting was held in Queenstown, NZ. As those who attended the meeting all know, the presentation sessions were jam packed with interesting and educational information on TROG trials and related topics in the main scientific meeting, and the very successful Technical and Clinical Trial Management Workshops. Presentations from these meetings are now available on the TROG website in the members section under "Minutes and Presentations".

TROG Member Contact Details:

Have you recently changed your email address or contact details? If so, please, visit the TROG website, login to the members section and update your details!

Trial in Profile
TROG 03.06 - Prostate TOAD

The timing of androgen deprivation study (TOAD) – is there a survival advantage in starting early androgen deprivation therapy in PSA relapsed patients compared to waiting? Which group has the better quality of life?

Mr Sterling has been coming to your clinic for about five years since completing his radiation therapy for low-intermediate risk prostate cancer at the age of 69. He is well, but you noticed that his PSA had increased from its nadir of 0.5 ng/ml at two years to 0.8 a year later, 1.5 ng/ml at year 4 and on this occasion it is 2.6 ng/ml. He asks what this means, you undertake re-staging CT scan and bone scan which are negative, and he asks 'what now?' Do you watch him? Do you offer androgen deprivation therapy? Can you advise him as to the likely course of the PSA change and its implications over the coming years? How will his quality of life be affected?

Fortunately as our treatments of primary prostate cancer become more successful, we are seeing fewer of these cases, but there are still a number of patients who will suffer a PSA relapse after definitive treatment. The fundamental question in the TOAD study remains unanswered: there is equipoise between starting up androgen deprivation immediately on the diagnosis of PSA relapse or waiting for significant disease progression.

TOAD has been open for accrual for six years, and has currently recruited just short of 250 patients, which is obviously proceeding too slowly, well beyond the TROG "diabolicals" lag time. Until recent months accrual was very steady, reflecting the continued uncertainty in timing of therapy commencement for these patients. This has been reflected in editorial comments from a number of eminent oncologists when discussing the issue, endorsing the need for completion of randomised trials to answer this question. We have recently suffered a further slowing, but have been helped serendipitously by the early closure of the sister study in Canada, ELAAT (early versus late androgen ablation therapy) because of slow recruitment. One of the productive Canadian centres is now putting patients on to TOAD, and we are preparing a formal agreement with the principal investigator to analyse our patient cohorts together. We hope by early next year to have over 300 patients on TOAD, and to proceed to the main analysis in 2013.

We are delighted with the integrity of the case record forms in terms of accuracy and completeness, which will enable preparation for analysis to proceed smoothly. We will be working with Madeleine King from PoCoG, on the quality of life analysis to ensure that this key component of the study receives the attention it deserves. We urge you to rally round once more and recruit just two more patients per centre in the next six months to achieve the accrual target and move us into the follow up phase. Many thanks to all contributors for their support to date.

If you would like more information regarding this trial please contact:

Trial Chair: Gillian.Duchesne@petermac.org

Trial Coordinator: Evan.kemp@cancervic.org.au

Protocol Amendments Approved:

Trial Title	Trial Chair	Trial Coordinator	Amendment Approval Date	Lead Group	New Protocol Version
TROG 03.06 - A collaborative randomised phase III trial: The timing of intervention with androgen deprivation in prostate cancer patients with a rising PSA.	Gill Duchesne	Evan Kemp	1st October 2009	VIC CC	Version 3: 1 October 2009
TROG 05.02 - A prospective single arm trial of involved field radiotherapy alone for stage I-II low grade non-gastric marginal zone lymphoma.	Michael MacManus	Marijana Vanevski	23rd February 2010	TROG	Amendment 1: 23 February 2010
TROG 07.02 - QUARTZ – Quality of life After RadioTherapy and/or Steroids	Tanya Holt	Kacy Baumann	1st December 2009	NCIC CTG	Version 3: 1 December 2009
TROG 07.03 - RadioHUM - Radiotherapy with Humidification in head and neck cancer.	Andrew Macann	Carol Fraser-Browne	17th June 2010	TROG	Amendment 1: 17 June 2010
TROG 08.09 - A randomised phase III trial of postoperative radiation therapy following excision of neurotropic melanoma of the head and neck (RTN2).	Bryan Burmeister	Janelle Meakin	17th December 2009	TROG	Amendment 1: 15 April 2010

If you have any queries in regard to any of these amendments, please contact the Trial Coordinator responsible for the particular trial.

Do you have a protocol amendment looming? Please contact Erin Nolan at erin.nolan@trog.com.au for any queries and submissions of protocol amendments for review and TROG approval.

Trials Approved for Activation

Trial Title	Trial Chair	Activation Date	Lead Group (s)	Collaborating Group(s)
TROG 10.01 - Multi-centre Feasibility study of online adaptive Radiotherapy for Muscle invasive bladder Cancer ("BOLART")	Farshad Foroudi	2nd February 2010	TROG	N/A
TROG 10.02 - RAPID - A multicentre randomised Trial to determine if Accelerated Partial Breast Irradiation, utilising 3D CRT, is as effective as whole breast irradiation following breast conserving surgery in women with ductal carcinoma in situ or invasive breast cancer with negative axillary lymph nodes.	Boon Chua	11th December 2008	OCOG	OCOG

Trials Approved for Development

A phase II Trial of the feasibility of breast conservation for locally advanced breast cancer using MRI and PET scanning to predict conservability, local control and disease free survival. (Verity Ahern)

Randomised Phase III high dose palliative radiotherapy versus concurrent chemotherapy & high dose palliative radiotherapy in good performance status patient with locally advanced or small volume metastatic non-small cell lung cancer (NSCLC) - not suitable for radical chemo/radiotherapy. (Margot Lehman)

Randomised Phase II weekly Cetuximab + RT and weekly Cisplatin + RT in locoregionally advanced HPV-associated Oropharyngeal Cancer. (Danny Rischin / June Corry)

A prospective study of the relationship between the radiotherapy planning target volume and sites of relapse in patients with Glioblastoma Multiforme treated with the Stupp protocol. (Gail Ryan)

If you would like any further information about these or any TROG trials, please visit our website www.trog.com.au where you will find updated protocols, contact details and trial related information.

Trials Recently Closed To Accrual

Trial Title	Trial Chair	Lead Group	Date Closed To Accrual
TROG 06.01 – Primary chemotherapy with Temozolomide vs radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: a phase III study. (EORTC 22033-26033)	Gail Ryan	EORTC	26th March 2010
TROG 08.07 - Randomised phase II trial of novel chemoradiotherapy regimens in the treatment of localised oesophageal cancer.	Michael Michael	AGITG	

2010 Trials Approved On Scientific Merit

SCORAD III –A randomised phase III study of single fraction radiotherapy compared to multi-fraction radiotherapy in patients with metastatic spinal cord compression. (Tanya Holt)

Randomised trial of dose and technique in post-prostatectomy salvage radiotherapy – " Psa DoT Com" (Scott Williams)

A prospective study of conservative surgery and targeted systemic therapy for early breast cancer – Molecular profiling for prognostication of local recurrence. (Boon Chua)

If you would like further information on trials approved on scientific merit please contact Jan Kilmurray
E-Mail jan.kilmurray@trog.com.au or Phone +61 2 4014 3909 or Friday's mobile 0401921111

2010 Publications Update

Congratulations to these authors and their respective research teams for all their hard work.
If your publication has been left off this list, please let us know and we will update our files immediately.
Keep up the good work!

Denham JW, Steigler A, Kumar M, Lamb DS, Spry NA, Tai K, Atkinson C, Turner S, Greer PG, Gleeson PS, D'Este C. **Measuring time to Biochemical Failure in the TROG 96.1 Trial: When should the clock start ticking?** Int. J. Radiation Oncology Biol. Phys Vol: 75 Issue: 4, 1008-1012, 2009.

Ebert MA, Harrison K, Cornes D, Howlett SJ, Joseph DJ, Kron T, Hamilton CS, Denham JW **Australasian multi-centre dosimetric intercomparison for pelvic radiotherapy - issues and logistics**, J Med Imag Radiat Oncol, 53(1); 119-13, 2009.

Denham JW, Steigler A, Wilcox C, Lamb DS, Joseph D, Atkinson C, Tai K-H, Spry NA, Gleeson PS, D'Este C. **Why are pre-treatment PSA levels and biochemical recurrence poor predictors of prostate cancer survival?** Cancer 115(19): 4477-4487, 2009.

Rischin D, Peters LJ, O'Sullivan B, Giralt J, Fisher R, Yuen K, Trotti A, Bernier J, Bourhis J, Ringash J, Henke M, Kenny L. **Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART):** A Phase III Trial of the Trans-Tasman Radiation Oncology Group. Journal of Clinical Oncology, Vol 28, No 18: 2989-2995, 2010.

Peters LJ, O'Sullivan B, Giralt J, Fitzgerald TJ, Trotti A, Bernier J, Bourhis J, Yuen K, Fisher R, Rischin D. **Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02**. Journal of Clinical Oncology, Vol 28, No 18: 2996-3001, 2010.

TROG Trial Progress Reporting
August 2010 – December 2010

Progress Reports for October TSC Meeting (coincides with TRM2010) (as of 31st August 2010)

Milestone	Date Due
TRM TSC Meeting	22nd October 2010
TSC Agenda circulated to TSC members	24th September 2010
Progress Reports Due	8th September 2010
Submissions for TSC agenda – TCOO review required*	31st August 2010
Progress Reports Sent	18th August 2010

*Documents that require review by TCOO include trial protocols in development, protocol amendments (including PICFs and GSA's) for open trials and all other documentation that requires TROG approval prior to distribution (such as advertising material and patient information brochures).

These timelines have been put in place to ensure that a thorough review can be conducted by TCOO staff. If you are unable to meet the above deadline for document submission please contact the TCOO to make other arrangements.

Protocols under development must be submitted to Jan.Killmurray@trog.com.au

All other documents must be submitted to Erin.Nolan@trog.com.au

Accrual Request as of 31st December 2010

Milestone	Date Due
Accrual Updates Due	7th January 2011
Accrual Updates Request sent	13th December 2010

TROG Committees

Board under Constitution Act

Position	Appointed
President (Chair Of Board)	Bryan Burmeister
Scientific Committee Chair	Gillian Duchesne
Ordinary Member (Australia)	Sandro Porceddu
Ordinary Member (NZ)	Andrew Macann
Affiliate Member	Tomas Kron
Chief Executive Officer	Rowena Amin
Consumer Representative	Sally Hodgkinson
Independent Director	TBA

TROG Scientific Committee

Position	Appointed
Scientific Chair	Gillian Duchesne
TROG President	Bryan Burmeister
Trial Development Portfolio	Sandro Porceddu
Publications Portfolio	June Corry
Grants Portfolio	Andrew Macann / Gillian Duchesne
Statistician	Richard Fisher
Medical Oncologist	Danny Rischin
Radiation Therapist	Kathryn Neilson
Medical Physicist	Annette Haworth
Diagnostic Imaging Specialist	Ming Wang
Research Manager	Kathy Hall
Quality Assurance Manager	Deidre Cornes
Consumer Representative	Sally Hodgkinson
TCOO Scientific Advisor	Chris Wratten
Quality of Life Chair	Madeleine King
Health Economics Chair	Deborah Schofield

TROG Publications Committee

Position	Appointed
Chair Person	June Corry
Scientific Chair	Gillian Duchesne
Statistician	Richard Fisher
Radiation Oncologist	David Christie
Secretary	Kathy Hall

TROG Central Operations Office

The following is a guide to the staff available to assist you with enquires regarding TROG membership and services. We look forward to talking to you!

RESEARCH STAFF

Research Manager:
Kathy Hall
Kathy.Hall@trog.com.au
Ph: +61 2 4014 3903

The key function areas that Kathy has overall responsibility for include: Trial Management and Conduct; TROG committees co-ordination and participation, TROG meeting organisation; communication with TROG members and others; any other research related issues that may arise.

Research Assistant:
Erin Nolan
Erin.Nolan@trog.com.au
Ph: +61 2 4014 3912

Please contact Erin with any questions or suggestions relating to the TROG website or clinical trial registration. Erin is also responsible for trial directory updates, progress reports and a number of other specific projects.

Policy, Procedures & Special Project Officer:
Olga Kovacev
Olga.Kovacev@trog.com.au
Ph: +61 2 4014 3904 (Tues/Wed)

Olga has responsibility for updating the TROG Policy and Procedures Manual as well as projects that provide resources to better assist and improve researchers capacity to be involved in TROG Clinical Trials.

Trial Development Coordinator:
Jan Kilmurray
Jan.Kilmurray@trog.com.au
Ph: +61 2 4014 3909 / Friday's 0401921111

Jan's role will be to develop processes which facilitate and streamline the trials development/activation process. Once your trial receives the "green light" at the ASM, Jan will work with you and your team to ensure the steps which are involved in trials development are met in a timely manner, and resulting in the earliest possible activation of that trial

QUALITY ASSURANCE STAFF

Quality Assurance Manager:
Deidre Cornes
Deidre.Cornes@trog.com.au
Ph: +61 2 4014 3921

Please contact Deidre for any enquiries regarding quality assurance, particularly to discuss the design and development of procedures and resources for new trials. Deidre is responsible for policy development and strategic planning in relation to QA and facilitating the ongoing development of central QA infrastructure for TROG. This includes management of the QA projects relating to the NHRMC Enabling Grant. Deidre leads the central QA team and is also the chair of the Quality Assurance Development Group (QADG) and the QA representative on the TROG Scientific Committee (TSC).

Assistant Quality Assurance Manager:
Melissa Crain
Melissa.Crain@trog.com.au
Ph: + 61 2 4014 3905

Please contact Melissa for any enquiries regarding quality assurance, particularly to discuss procedures and resources for new trials. Melissa is facilitating the implementation of CQMS in the TROG research program and is also involved in organising the Technical Research Workshop.

Quality Assurance Research Assistants:
Kelly Barker, Claudia Koller, Tracy Williams
Kelly.Barker@trog.com.au
Ph: +61 2 4014 3918 Mon/Tues
Claudia.Koller@trog.com.au
Ph: +61 2 401 43907
Tracy.Williams@trog.com.au
Ph: +61 2 4014 3906

Kelly, Claudia, and Tracy are responsible for the design, coordination and administration of QA programs in several trials. They also participate in associated research projects, including the development of CQMS and new QA resources. Please contact them for any queries regarding quality assurance.

Quality Assurance Radiation Therapist:
Daniela Rossetti
Daniela.Rossetti@trog.com.au
Ph: +61 2 4014 3918 Thu/Fri

Dan provides assistance and technical advice to the QA Office in a range of areas including QA review procedures, new protocol development, the commissioning of 3D review software and the resolution of technical RT queries in relation to case reviews. Please contact Dan for any queries regarding quality assurance.

Quality Assurance Medical Physicist:
Joan Hatton
Joan.Hatton@trog.com.au
Ph: +61 2 4014 3901 Wed/Thu

Joan provides assistance and advice to the QA Office including protocol design, QA program design and the implementation of QA resources such as the SWAN and generic dosimetric audits. Joan also assists with the resolution of technical RT queries. Please contact Joan for any queries regarding quality assurance.

Quality Assurance Radiation Oncologist:
Anne Capp
Anne.Capp@mater.health.nsw.gov.au
Ph: + 61 2 4014 3643

Anne is an advisor to the QA Office, providing assistance in protocol development, QA program design, and the

(Continued on page 16)

TROG Central Operations Office

The following is a guide to the staff available to assist you with enquires regarding TROG membership and services. We look forward to talking to you!

(Continued from page 15)

conduct of central reviews of radiotherapy trial treatment.

BUSINESS SERVICES STAFF

Chief Executive Officer:
Rowena Amin
Rowena.Amin@trog.com.au
Ph: +61 2 4014 3913

Rowena manages the day to day operations of TROG, its people and resources with responsibility for developing and implementing strategic, operational and business plans approved by the TROG Board. Rowena is responsible for ensuring the company's compliance with legal and regulatory obligations.

Administration Officer / Conference Coordinator:
Alyson Segrott
Alyson.Segrott@trog.com.au
Ph: +61 2 4014 3911

Please contact Alyson in relation to organisation of events and registrations for Annual Scientific Meeting and Trials Review Meeting, teleconferences and administration assistance.

Accountant:
Kim Reeves
Kim.Reeves@trog.com.au
Ph: +61 2 4014 3908

Please contact Kim in relation to all membership, financial and budget queries or assistance in preparing a budget for your trial.

PROJECT OFFICER

NZ Project Officer:
Janfrey Doak
trognz@trog.com.au
Ph: +64 3 378 6291

JD is responsible for investigating TROG's role in the New Zealand (NZ) research environment. Please contact her with any queries specific to NZ research activities.

ANROTAT Project TEAM

Special Project Manager
Mel Grand
Mel.Grand@trog.com.au
Ph: + 61 448 460 371

Mel is responsible for overseeing and advising the ANROTAT Project team and managing the overall development and conduct of the project. Mel reports on behalf of the project team to the Executive Advisory Group (EAG).

Special Project Officer (Senior)
Michelle Hall (Mon, Tues, Thurs and Fri)
Michelle.Hall@trog.com.au
Ph: + 61 2 4014 3922

Michelle is responsible for the coordination of the development of the ANROTAT protocol (including Patient Information Sheet and Consent Forms and Case Report Forms) and for the ethics submission of the final ANROTAT Protocol in line with the HoMER pilot. Reporting directly to the TROG Special Projects Manager, Michelle also assists with the support and guidance of the ANROTAT Project Team.

Special Project Officer (Junior)
Haylea Cleaver
Haylea.Cleaver@trog.com.au
Ph: + 61 2 4014 3922

Haylea's role is to assist in the development of the framework and the protocol, liaise with the expert sub-groups in terms of organising meetings, conducting literature reviews and preparing agendas. Haylea will also be responsible for conducting site visits with the TROG QA Physicist in order to carry out site specific dosimetry audits.

Administration Officer
Celia Burrell
Celia.Burrell@trog.com.au
Ph: + 61 2 4014 3917

Celia is responsible for providing administrative support to the ANROTAT Project Team and to the various expert groups and sub-groups by taking minutes, arranging travel and accommodation and managing correspondence.

Administration Officer
Lou Macgregor
Louise.MacGregor@trog.com.au
Ph: + 61 2 4014 3914

Lou is responsible for providing administrative support to the ANROTAT project team and, where required, the expert groups and subgroups. In addition to this role, Lou continues to provide a high level of support to the TROG QA and Research teams by managing the entry of data into the Central Quality Management System (CQMS) and coordinating the Clinical Trial Agreement process.

TROG Central Operations Office
Calvary Mater Newcastle
Building 7, Level 5
Locked Bag 7
HRMC NSW 2310

Phone: +61 2 4014 3911
Fax: +61 2 4014 3902

TROG CANCER RESEARCH

UPCOMING EVENTS

21 — 22 October 2010

TROG Trials Review Meeting

Preston, Victoria

11 — 14 April 2011

TROG Annual Scientific Meeting

Adelaide, South Australia

Please click on the link below for other trial group meeting information:

http://www.trog.com.au/Default.aspx?tabid=120

TROG would like to acknowledge the support of our sponsors in 2010

If you would like to sponsor TROG please contact

Rowena Amin
CEO
Phone: +61 2 4014 3913
Email: Rowena.Amin@trog.com.au

2010 Corporate Partners

VARIAN medical systems

AstraZeneca

Hospira